Musings from The Power List: Michael May

• September 22, 2026

Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

• by Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, Paul Zuidgeest, Frits Smit, Lioe-Fee de Geus-Oei, Tom van der Hulle

• September 16, 2026

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy

• by Manfred Hauben, Rave Harpaz, Robert Weber

• September 17, 2026

Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

• September 15, 2026

• 5 min